

Adding ImmunoCAP™ **Der p 23\*** to your test profile


# House Dust Mite

Allergens for AIT\*\*? Risk for asthma?  
Knowing the sensitization profile can help  
you decide on patient management.<sup>1-4</sup>

By adding ImmunoCAP™ **Der p 23\*** to your test  
profile you can improve diagnostic certainty.<sup>4-6</sup>

\*ImmunoCAP Allergen d209, Allergen component rDer p 23, House dust mite  
\*\* Allergen Immunotherapy

Find out more at [thermoscientific.com/phadia](https://thermoscientific.com/phadia)



ImmunoCAP®  
ALLERGEN COMPONENTS

**ThermoFisher**  
SCIENTIFIC

ImmunoCAP™  
Whole Allergens

**Dermatophagoides pteronyssinus (d1) and Dermatophagoides farinae (d2)**

ImmunoCAP™  
Allergen Components

Der p 1\* (d202) / Der p 2\* (d203) / Der p 23\* (d209)

Der p 10 (d205)

Specific markers

Cross reactive marker

Clinical implications

Choice of AIT

- Differentiation between Der p 1, 2 and 23 sensitization helps choose appropriate AIT.<sup>1,2</sup>
- Der p 2 sensitized patients may benefit from AIT based on purified mite body cultures<sup>7-9</sup> or carefully standardized pharmaceuticals.<sup>10,11</sup>
- Der p 23 amount in fecal particles/bodies is low and may therefore be underrepresented<sup>#</sup> in AIT.<sup>6</sup>

Assess risk for asthma

- Early sensitization to Der p 1, 2 & 23 is associated with asthma development.<sup>3</sup>
- Asthmatic patients are sensitized to more components than those without asthma.<sup>4</sup>

Further examination needed

- Cross-reactivity between HDM, crustaceans, insects and molluscs.
- If Der p 10 is dominant, food allergy can be suspected.

1. Asero R, *Eur Ann Allergy Clin Immunol.* 2012;44(5):183-7. 2. Schmid-Grendelmeier P, *Hautarzt.* 2010;61(11):946-53. 3. Posa D, et al. *J Allergy Clin Immunol.* 2017;139:541-94.4. Resch Y, et al. *J Allergy Clin Immunol.* 2015;136:1083-91. 5. Becker S et al. *Int Arch Allergy Immunol.* 2016;170(2):132-7. 6. Weghofer M, et al. *J Immunol.* 2013;190(7):3059-67. 7. Brunetto R, et al. *Allergy* 2010;65:184-90. 8. Casset A, et al. *Int Arch Allergy Immunol.* 2012;159:253-62. 9. Weber B, et al. *Allergy.* 1998;53 (Suppl 43):25. 10. Henmar H, et al. *Int Arch Allergy Immunol.* 2016;169(1):23-32. 11. Canonica GW., et al. *Expert Rev Clin Immunol.* 2016 Aug;12(8):805-15. \*High cross-reactivity between Der p 1/Der f 1, Der p 2/Der f 2, Der p 23 / Der f 23. #Der p 23 content of extracts has not been studied.